Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Feb 06, 2020 10:53 AM IST | Source: PTI

Granules Pharmaceuticals, Inc gets USFDA nod for Colchicine tablets

Familial mediterranean fever is a genetic disorder that causes recurrent episodes of fever that are typically accompanied by pain in the abdomen, chest, or joints.

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Granules India on Thursday said its wholly owned foreign arm has received US health regulator's approval for Colchicine tablets, used in the treatment of familial mediterranean fever.

Familial mediterranean fever is a genetic disorder that causes recurrent episodes of fever that are typically accompanied by pain in the abdomen, chest, or joints.

"The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc, a wholly owned foreign subsidiary of Granules India Ltd for Colchicine tablets USP, 0.6 mg," the company said in a regulatory filing.

Close

The filing further said that "it is bioequivalent to the reference listed drug product (RLD), Colcrys tablets, 0.6 mg, of Takeda Pharmaceuticals USA, Inc."

Shares of Granules India were trading at Rs 159.55 a piece on BSE, up 3.74 percent from the previous close.

Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Feb 6, 2020 10:47 am
Sections
Follow us on